GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scancell Holdings PLC (LSE:SCLP) » Definitions » Float Percentage Of Total Shares Outstanding

Scancell Holdings (LSE:SCLP) Float Percentage Of Total Shares Outstanding : 0.00% (As of Apr. 26, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Scancell Holdings Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Scancell Holdings's float shares is 0.00 Mil. Scancell Holdings's total shares outstanding is 928.98 Mil. Scancell Holdings's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Scancell Holdings's Insider Ownership is 14.72%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Scancell Holdings's Institutional Ownership is 0.32%.

Scancell Holdings Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Scancell Holdings's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=0.00/928.98
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scancell Holdings (LSE:SCLP) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scancell Holdings PLC (LSE:SCLP) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
LSE:FUM LSE:REDX LSE:HVO LSE:OBD LSE:ARIX LSE:4BB LSE:ETX LSE:AREC LSE:SBTX LSE:DEST OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
SCLP.GB:UK SCP:Germany
Address
Sanders Road, Unit 202, Bellhouse Building, Oxford Science Park, Oxford, GBR, OX4 4GD
Website
https://www.scancell.co.uk
Scancell Holdings PLC is engaged in the discovery and development of novel vaccines for the treatment of cancer. The company is exploiting the unrivalled potential of the immune system to seek out and destroy cancer using two proprietary immuno-oncology platforms: ImmunoBody and Moditope. Its potent innovative DNA-based ImmunoBody therapies generate ultra-high avidity T cell responses that target and eliminate cancerous tumors. Its Moditope platform technology overcomes the immune suppression induced by tumors themselves, allowing activated T cells to seek out and kill tumor cells that would otherwise be hidden from the immune system.

Scancell Holdings (LSE:SCLP) Headlines

No Headlines